Cargando…

Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care

INTRODUCTION: This study aimed to address therapeutic inertia in the management of type 2 diabetes (T2D) by investigating the potential of early treatment with oral semaglutide. METHODS: A cross-sectional survey was conducted between October 2021 and April 2022 among specialists treating individuals...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morieri, Mario Luca, Candido, Riccardo, Frontoni, Simona, Disoteo, Olga, Solini, Anna, Fadini, Gian Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597935/ https://www.ncbi.nlm.nih.gov/pubmed/37848758 http://dx.doi.org/10.1007/s13300-023-01490-6

Ejemplares similares

Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies
por: Fadini, Gian Paolo, et al.
Publicado: (2021)

Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care
por: Morieri, Mario Luca, et al.
Publicado: (2022)

Deep-learning-based natural-language-processing models to identify cardiovascular disease hospitalisations of patients with diabetes from routine visits’ text
por: Guazzo, Alessandro, et al.
Publicado: (2023)

Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?
por: Giaccari, Andrea, et al.
Publicado: (2021)

Challenges and opportunities in real‐world evidence on the renal effects of sodium‐glucose cotransporter‐2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2021)

Improved prediction of long-term kidney outcomes in people with type 2 diabetes by levels of circulating haematopoietic stem/progenitor cells
por: Bonora, Benedetta Maria, et al.
Publicado: (2023)

Time-series analysis of multidimensional clinical-laboratory data by dynamic Bayesian networks reveals trajectories of COVID-19 outcomes
por: Longato, Enrico, et al.
Publicado: (2022)

Improved long-term cardiovascular outcomes after intensive versus standard screening of diabetic complications: an observational study
por: Morieri, Mario Luca, et al.
Publicado: (2019)

Time-resolved trajectory of glucose lowering medications and cardiovascular outcomes in type 2 diabetes: a recurrent neural network analysis
por: Longato, Enrico, et al.
Publicado: (2022)

Updating obesity management strategies: an audit of Italian specialists
por: Busetto, Luca, et al.
Publicado: (2022)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Obesity management: Attitudes and practice of Italian endocrinologists
por: Chianelli, Marco, et al.
Publicado: (2023)

Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients
por: Marzullo, P., et al.
Publicado: (2022)

Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes
por: Candido, Riccardo, et al.
Publicado: (2023)

Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
por: Verma, Subodh, et al.
Publicado: (2022)

Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)
por: Janić, Miodrag, et al.
Publicado: (2022)

Prevalence and impact of diabetes among people infected with SARS-CoV-2
por: Fadini, G. P., et al.
Publicado: (2020)

Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
por: Di Folco, Ugo, et al.
Publicado: (2022)

Physicians’ misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes
por: Morieri, Mario Luca, et al.
Publicado: (2022)

Prevalence of Cardiovascular Risk Factors and Related Medical and Lifestyle Interventions Among Italian Cardiovascular Specialists: A Proof-of-Concept Study
por: Agabiti Rosei, Claudia, et al.
Publicado: (2023)

Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes
por: Morieri, Mario Luca, et al.
Publicado: (2021)

Correction to: Physicians’ misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes
por: Morieri, Mario Luca, et al.
Publicado: (2022)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

Semaglutide for type 2 diabetes
Publicado: (2020)

Semaglutide-associated bullous pemphigoid
por: Burruss, Clayton P., et al.
Publicado: (2021)

Semaglutide-eye-catching results
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2023)

Emerging Anesthesia Risks with Semaglutide
por: Fezza, Reed, et al.
Publicado: (2023)

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
por: Husain, Mansoor, et al.
Publicado: (2020)

Management of Nonceliac Gluten Sensitivity by Gastroenterology Specialists: Data from an Italian Survey
por: Branchi, Federica, et al.
Publicado: (2015)

Why diabetes outpatient clinics should not close during pandemic crises
por: Fadini, G. P., et al.
Publicado: (2021)

Pharmacogenetics of Cardiovascular Prevention in Diabetes: From Precision Medicine to Identification of Novel Targets
por: Morieri, Mario Luca, et al.
Publicado: (2022)

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
por: Lingvay, Ildiko, et al.
Publicado: (2022)

Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide
por: Verma, Subodh, et al.
Publicado: (2021)

Fixed versus flexible combination of GLP‐1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study
por: Morieri, Mario Luca, et al.
Publicado: (2019)

Hemoglobin A(1c) variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study
por: Penno, Giuseppe, et al.
Publicado: (2013)

Acute Kidney Injury Associated With Semaglutide
por: Leehey, David J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rgvakjbpq5goo06t9jfh5ip8in